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LIST OF ABBREVATIONS 
1. LFT                Liver function tests   
2. CCF                      Congestive cardiac failure 
3. CAHD                   Coronary artery heart disease 
4. CP                         Cor pulmonale 
5. RHD                     Rheumatic heart disease 
6. CM                        Cardiomyopathy 
7. HHD                     Hypertensive heart disease 
8.  AST/SGOT         Aspartate amnotransferase/Serum glutamic  
 oxaloacetic transaminase 
9. ALT/SGPT     Alanine aminotransferase/Serum glutamic pyruvate  
 transaminase 
10. ALP                      Alkaline phosphatase 
11. GGT              Gamma glutamyl transpeptidase. 
12. ECG                      Electrocardiogram 
13. CLN                     Centrilobular necrosis 
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INTRODUCTION 
 Liver is the biggest organ in human body with a mass of nearly 1.5 kg2.  
Liver has a massive functional reserve and regenerating capacity. It plays a 
major role in maintaining the  normal physiology and metabolic homeostasis 
of human body. It is also referred to as the custodian of milieu interior7. 
Hence hepatic diseases can have a major impact on the homeostasis of body. 
Similarly disorders in other systems can adversely affect the liver as well. 
 Cardiac failure both chronic and acute can cause hepatic dysfunction 1. 
Twenty five percent of total cardiac output goes to the liver,hence any 
decrease in cardiac output leads to decreased liver perfusion.by means of 
vasoregulatory mechanisms and  enhanced extraction of oxygen  liver can 
tolerate variations in blood flow.  
 But hepatic damage occurs when the threshold levels are crossed.In 
right heart decompensation raised backpressure causes congestion of the 
sinusoids and hepatocyte hypoxia. Left heart failure produces decreased 
cardiac output further causing decreased blood flow to the liver producing 
hypoxia. Both this mechanisms leads eventually into centrilobular liver cell 
necrosis. The most susceptible region of the liver lobule to hypoxic insult is 
the zone three of acini because of the peculiar arrangement of blood flow in 
the liver. 
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 In the present study ,the consequence of congestive cardiac failure on 
liver function were studied in a group of 60 patients and was analysed and 
compared with various parameters.Differing causes of heart failure of various 
duration were included in the study. Follow up of the cases were done for a 
period of one week and measurements were repeated at the end of one week. 
Changes in the values were recorded and an attempt is done to find the 
prevalence of liver function abnormalities in these subjects,its correlation 
with various parameters and prognostic significance of liver function on 
cardiac failure. 
  A proper knowledge and understanding of structure and functions of 
liver,liver parameters,etiologies and different forms of heart failure and their 
presentation ,as well as the mechanism and pathology of liver in cardiac 
failure is inevitable before assessing the liver function abnormalities in 
congestive cardiac failure. 
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AIMS AND OBJECTIVES 
 
1. To study the prevalence of liver function abnormalities in congestive 
cardiac failure patients  attending  Tirunelveli Medical College 
Hospital 
2. To assess the correlation of liver function tests with etiology , duration  
and NYHA Class of  cardiac failure 
3. To study the pattern of elevation of liver enzymes in cardiac failure.   
4. To study the prognostic importance of liver function abnormalities in 
cardiac failure 
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REVIEW OF LITERATURE 
 
 
STRUCTURE AND FUNCTIONS OF LIVER 
 The liver weighing 1.2–1.5kg forms one-fiftieth of  the whole body 
mass and is the biggest structure in human being2.  Liver is situated in the 
right upper abdomen .It extends from the fifth ICS in the MCL to right rib 
boundary. During inspiration  the lower margin of the liver crosses the rib 
border. Other surfaces of  liver  fit  alongside the diaphragm and are even and 
rounded  . Right kidney, colon and duodenum form markings on the posterior 
surface of right lobe of liver and on left lobe stomach3. Peritoneal reflections 
like the right and left triangular ligaments ,coronary ligaments and the 
falciform ligament hold the liver in position. The liver   is connected to the 
upper portion of  duodenum by the hepatoduodenal ligament. The portal vein, 
hepatic artery, bile duct, lymphatic vessels and nerves are present in the free 
border of this ligament. The falciform ligament divides the liver  into left and 
right lobes2 .The liver is classified into eight segments, supplied by  hepatic 
and portal branches and bileductules and  hepatic venules present among the    
segments3. 
 
 
5 
 
   
 
 
 
 
 
 
6 
 
 Blood circulation to the hepatic tissue has peculiar features.It has both 
systemic and portal circulation3.Arterial blood is supplied bythe hepatic 
artery, originating from the coeliac axis .The portal circulation consists of 
venous blood from spleen, intestines etc. The porta hepatis fissure,  which 
lies on undersurface of the right lobe is the portal of entry for this vessels9. 
On entry into liver hepatic artery and portal vein divide into right and left 
lobe branches. Common bile duct is formed by  confluence of right and left 
hepatic ducts in the porta. Sympathetic fibres from ganglia T7–T10 supplies 
the liver through the hepatic plexus1. 
  The CBD(common bile duct)  is situated  in front and right side of 
hepatic artery and in front of portalvein. Within the portal tracts intrahepatic 
bile ducts strictly track the path of intrahepatic arteries and portal veins. Right 
and left hepatic veins drain venous blood from the liver. They arise from 
posterior aspect of liver and drain into IVC(inferior vena cava) close to its 
entry point to right atrium. Collection of  lymph nodes nearby portahepatis 
and coeliac axis drain the lymph. The mediastinal glands receives superficial 
hepatic lymph vessels traverse  the diaphragm .One more group drains in 
some minor glands nearby IVC intrathoracic part2.3. 
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 Except in three places the liver is entirely enclosed within peritoneum.  
There is a bare area near the IVC fossa where liver is in straight contact with 
the diaphragm. IVC fossa and gallbladder fossa lacks peritoneal covering1. 
The peritoneal ligament and the intra-abdominal pressure keep the liver in 
position. 
FUNCTIONAL ANATOMY 
 The model  of hepatic  lobular architecture was put forward by 
Kierman et al29 in 1833.Thepyramidal lobules comprises of a peripheral 
portal tract made up of portal vein radicle, hepatic artery branch and the bile 
duct and a central tract of the hepatic vein3. Blood-containing sinusoids and 
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columns of hepatocytes spread between above two structures. The hepatic 
vein radicles and their adventitia occupy  the central hepatic canals. They are 
enclosed by hepatocytes. The hepatic arteriole, the portal vein radicle and bile 
duct along with a few number of cells and connective tissue form the portal 
triad. The major portion of  liver about 60% is made up of hepatocytes3,9 
.They are nearly  30mm  in diameter and multilateral. The liver cells has three 
surfaces: each fronting the canaliculus, the sinusoid and space of Disse, 
neighbouring hepatocytes respectively. The lifetime of hepatocytes  nearly 
150 days. They lack basement membrane2. 
 
 
 Endothelial cells line the sinusoids. The sinusoids contain the Kupffer 
cells(phagocytic cells of thereticulo-endothelial system), the fat storing 
cells(hepatic stellate cells, Ito cells or  lipocytes), liver cells and sinusoidal 
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endothelial cells. Space of Disse is a tissue space between liver cells and 
endothelium of  sinusoids. Connective tissue around the portal region 
contains liver lymphatics which has an endothelial lining. Lymphatics receive 
lymph through the endothelium. The division of the hepatic artery delivers 
blood to  the contents in  portal tracts forming a network surrounding  biliary 
ductules .These arterioles drains into sinusoids at multiple points .Portal veins 
and hepatic arterioles do not  anastamose directly2.  
 
 Bile canaliculi are the main portals of elimination of liver. They are 
channels between the apposition  surfaces of hepatocytes with no separate 
lining. The cytoskeleton of liver cells  is made up of  microfilaments  
supporting  the cell membrane .Microvilli are found on the  exterior of cells12. 
Canals of  Hering are thin-walled terminal bile ducts or ductules lined with 
cuboidal epithelium that drain the intralobular canaliculi which eventually 
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end in bile ducts in the portal canals Desmosomes, tight junctions and gap 
junctions  separate canaliculi  from other cell surface. 
 Functionally liver is structured into acini, with hepatic arterial and 
portal venous blood entering the acinus from the portal areas which constitute 
zone1 and flows through the sinusoids to the  terminal hepatic veins zone39 . 
The intervening liver cells constitute zone2. Hence zone3 of liver is 
susceptible to toxic and anoxic insult. Bile flows in the reverse direction from 
zone3 to zone1. The cells in the border of acini , zone3 differ in function 
from those of cells in  zone 1. TCA cycle enzymes are more  in  periportal 
zone . Glutamic synthetase  is  present  in zone 3. Perivenous zone is 
susceptible to anoxic injury. Congestive  heart  failure disturbs zone 3 of the  
hepatic acini  leading  to distinctive  features 9. 
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LIVER  FUNCTIONS 
 Liver  cells  execute  many  essential  roles in  maintaining  
homeostasis and well-being. 
SYNTHETIC  FUNCTIONS 
 The synthesis of proteins like carrier proteins,  albumin, hormones,  
growth factors, coagulation factors, bile and transporters  like  bileacids, 
cholesterol, lecithin, phospholipids1. 
DIGESTIVE FUNCTIONS 
 Nutrients  like glucose, glycogen, lipids, cholesterol, amino acids 
stored and metabolized by liver1,2. Liver also carries out  metabolism and 
conjugation of lipophilic compounds (bilirubin, anions, cations, drugs) 
EXCRETORY FUNCTIONS 
 This include  metabolism of  hormones including insulin and others 
Bilirubin  undergo conjugation  in the  liver to form mono and di 
glucoronides which is eliminated through bile. The liver metabolises and 
detoxify  toxic substances through reactions like  methylation. It  also act 
upon  drug  products  and detoxify them  through a process referred to as drug 
metabolism. The drugs and toxic products are thus metabolized and  
conjugated  and eliminated in urine or bile1,3 .The site of  Urea cycle where 
conversion of ammonia to urea occurs  is  in the liver. 
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STORAGE 
 Storage  of an array of various substances occur in the  liver which 
includes glucose as  glycogen, vitamin B12, vitamin A, vitamin K, vitamin D, 
copper and iron. 
IMMUNE FUNCTIONS  
 The liver plays a major role in immunological reactions. In the liver 
RES (reticuloendothelial system) is constituted mainly by cells that are 
immunologically reactive. Liver acts as a 'sieve' for antigens reaching it 
through the portal circulation1.  
LIVER FUNCTION TESTS 
 The evaluation and management of patients with hepatic dysfunction is 
done by means of a variety of liver function tests. The tests  are used to (1) 
distinguish the presence and absence  of liver illness, (2) differentiate  among 
a variety of liver disorders, (3) estimate  the  amount  of  hepatic damage, and 
(4) monitor the outcome  following  treatment48. The constellation of 
laboratory tests that involve hepatic synthetic function (serum albumin and 
prothrombin time), liver enzymes, and the serum bilirubin level is referred to 
as liver biochemical tests or liver function tests .The serum albumin and 
prothrombin time measures protein synthesis, serum bilirubin measures 
hepatic conjugation and excretion. Liver dysfunction is characterized by 
abnormalities of bilirubin ,albumin and prothrombin time. Liver failure is 
incompatible with life and hepatic functions are intricate and varied to be 
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substituted  by a mechanical pump ; dialysis membrane or fabrication of 
instilled proteins, growth factors and proteins1. 
Tests Centered on Conjugation and Elimination Purposes 
SERUM BILIRUBIN 
 Bilirubin, a yellow  breakdown product of  heme catabolism and is 
present  in  blood in two forms—conjugated and unconjugated. The 
unconjugated form or the indirect fraction, does not dissolve   in water and is 
carried by albumin in the circulation. The conjugated  or direct bilirubin 
fraction dissolves in water  and is eliminated  by  renal system. Estimated  by 
the  van den Bergh method, the total serum bilirubin concentration is 
normally<17mol/L (1 mg/dL).Of these  30%, or 5.1mol/L (0.3 mg/dL) is 
constituted by direct-reacting bilirubin 48. 
 Rise of the indirect  fraction of bilirubin is hardly due to hepatic 
dysfunction.  Isolated increase  of indirect bilirubin is found predominantly in 
hemolytic conditions and genetic disorders like Crigler-Najjar and Gilbert's 
syndromes. Isolated indirect hyperbilirubinemia (bilirubin increased but 
<15% conjugated) must warrant adiagnosis of hemolysis . An isolated 
indirect hyperbilirubinemia  without hemolysis  can be ascribed to Gilbert's 
syndrome and no additional assessment is needed. 
 Isolated direct hyperbilirubinemia  usually indicates  hepatic  or biliary 
tract disease.  The passage of direct bilirubin into the biliary canaliculi is the 
rate limiting step in bilirubin breakdown. Hence increase in the conjugated 
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form  can be seen in almost  any  kind of hepatic disorder. Both direct and 
indirect forms of the bilirubin is likely to be elevated in most of liver disease. 
SERUM ENZYMES 
 The liver comprises of numerous enzymes, of which some are found in 
the serum in small concentrations. These enzymes  act like other serum 
proteins with no known function . These enzymes  are dispersed in the 
interstitial fluid ,plasma  and have distinctive half-lives, typically estimated in 
days. Enzymes  are possibly cleared by cells in the reticuloendothelial 
system. The increase  in particular enzyme action in the serum is assumed to 
chiefly mirror its increased rate of entry into serum from injured hepatocytes 
Serum enzyme tests can be assembled into three classes: (1) enzymes whose 
rise in serum mirrors injury to hepatic cells, (2) enzymes whose rise in serum 
mirrors cholestasis, and (3) enzyme tests with no specific  pattern.  
 Enzymes that indicates destruction to Hepatocytes 
 The  transaminases (aminotransferases)  are reliable   pointers of liver 
cell injury. These tests are of great use in differentiating   liver ailments like  
hepatitis. They include the aspartate aminotransferase (AST or SGOT) and 
the alanine aminotransferase (ALT or SGPT). SGOT  is identified in tissues 
including liver cells, cardiac muscle, skeletal muscle, kidneys, brain, 
pancreas, lungs, WBC and RBC  in descending  order of concentration.  
SGPT  is present  chiefly in the hepatocytes. The aminotransferases are 
routinely found in serum in small amounts. They  are delivered into the 
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circulation in larger amounts when there is injury to the hepatocyte  
membrane leading to  easy permeability. Hepatocyte necrosis is not needed 
for the discharge of the aminotransferases, and the correlation between the 
amount of hepatocyte damage and the level of the aminotransferases is poor. 
Hence, the outright increase in aminotransferase has nil prognostic 
implication in acute hepatocellular conditions. Any kind of liver cell  damage 
can produce a modest  rise in the serum aminotransferases.Values of up to 
300 U/L  can  be present in any  kind  of hepatic disorder and are 
nonspecific49 .  Studies have revealed that fatty liver disease is the most likely 
explanation for mild ALT elevations in asymptomatic blood donors50. 
 Remarkable rises with aminotransferases > 1000 U/L is  seen almost 
absolutely in conditions  linked with widespread hepatocellular damage such 
as31 
1. hepatic damage due to ischaemia  
2. hepatic injury secondary to toxins and medications 
3. (3)hepatitis due to viral infections. 
 The estimation  of transaminase  increase  can be of great use  in 
diagnosis. Usually ALT is greater than or equivalent to the AST in acute liver 
cell conditions. An AST:ALTproportion > 2:1 is indicative whereas a 
proportion> 3:1 is greatly indicative  of alcoholic liver disease. In alcoholic 
liver disease AST is  hardly>300 U/L and the ALT is usually within  normal  
values. A low serum ALT level is caused by an alcohol-induced deficit of 
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pyridoxal phosphate.The transaminases are commonly not significantly raised 
in obstructive jaundice  except  in acute stage of biliary blockade due to the 
transport of a gallstone into the common bile duct where the transaminases 
can temporarily be raised upto 1000–2000 U/L  limit48,49. Nevertheless, 
transaminases fall rapidly, and the hepatic  function tests  progress into  
cholestatic  picture. 
ENZYMES IN CHOLESTASIS 
 The actions of  3 enzymes  are typically raised in cholestasis. They 
include Gammaglutamyl transpeptidase, Alkaline phosphatase and 5'-
nucleotidase. GGT is sited in the endoplasmic reticulum and in epithelial 
cells of biliary canaliculi whereas  ALP and 5-nucleotidase are present in or 
adjoining the biliary canalicular membrane of liver cells. GGT rise in serum 
is less precise for cholestasis when compared to alkaline phosphatase or 5'-
nucleotidase due to its  more widespread distribution  in the hepatocytes.The  
alkaline phosphatase  in serum comprises  of several discrete isoenzymes  
present in the  bone, hepatic cells, small bowel and placenta. Above the age 
of 60 persons may have a slightly raised alkaline phosphatase . Persons with 
blood groups B and O may show a rise of  serum alkaline phosphatase 
following an oily meal because of inflow of bowel ALP into the circulation. 
Physiological rise is seen  in adolescents and children with fast bone 
growth,due to  bone ALP and in normal pregnancies because of  entry of 
placental ALP.Increase in hepatic ALP  is not entirely precise for cholestasis, 
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and smaller than threefold rise is demonstrated in nearly any kind of hepatic 
disorder. ALP  rise more than four times seen mainly in patients with 
cholestatic  hepatic diseases, carcinomas and amyloidosis, and Paget's disease 
of the bone. The liver isoenzyme  is elevated in hepatic diseases.The 
identification of the cause of  raised isoenzymes  is useful, if increased ALP  
is the only anomalous outcome in an outwardly healthy subject .This can be 
advanced in numerous methods. The fractionation of the alkaline phosphatase 
by electrophoresis is one method. Another method  is to differentiate 
isoenzymes by there varied susceptibility to inactivation by heat. A heat-
stable fraction intensely points that either placenta or a tumor is the cause of 
the raised enzyme in serum. The heat labile fractions are liver, intestinal and  
bone ALPs. The most sensitive being bone. The measurement of serum 5'-
nucleotidase or GGT is the  best  proven  and most accessible method .In 
disorders other  than  hepatic disorders they  are hardly raised.  An  isolated 
elevation of ALP  of hepatic  origin  without icterus or raised  transaminases 
usually indicates  initial stages of cholestasis and rarely liver permeation by  
granulomas or malignancies1 . Other conditions that cause a sole rise in  
alkaline phosphatase are Diabetes,  Hodgkin's disease, amyloidosis, 
hyperthyroidism, inflammatory bowel disease, congestive heart failure etc. 
 The level of serum alkaline phosphatase elevation is not helpful in 
distinguishing between intrahepatic and extrahepatic cholestasis. There is 
essentially no difference among the values found in obstructive jaundice due 
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to cancer, common duct stone, sclerosing cholangitis, or bile duct stricture. 
Values are similarly increased in patients with intrahepatic cholestasis 
secondary to transplant rejection, hepatitis due to drugs, inflammatory bowel 
disease ,primary biliary cirrhosis  and  ethanol related  steatonecrosis1,2,9. 
Values are also greatly elevated in hepatobiliary disorders seen in patients 
with AIDS (e.g., AIDS cholangiopathy due to cytomegalovirus or 
cryptosporidial infection and tuberculosis with hepatic involvement). 
Tests centered on synthetic purposes of   Liver 
SERUM ALBUMIN 
 Hepatocytes produce and secrete 10 g of albumin per day. In patients 
with hepatic decompensation, albumin synthetic capacity decreases  resulting 
in hypoalbuminemia. However, the serum albumin level also can be lowered 
by extrahepatic conditions  such as malnutrition, enteropathy, renal disease, 
and hormonal disturbances. Therefore, hypoalbuminemia is not a precise 
pointer of liver dysfunction. As the  half-life of  serum albumin is  nearly 20 
days, the serum albumin cannot be taken as a consistent marker of  liver 
synthetic function in subjects with acute hepatic damage. However, in 
subjects with chronic hepatic disease the serum albumin value  is useful as a 
predictive marker of  prognosis. 
 Prealbumin, like albumin, is synthesized by the liver but has a shorter 
half-life. Serum prealbumin levels can be influenced by several extrahepatic 
factors and therefore are not used widely as a marker of liver dysfunction. 
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SERUM GLOBULINS 
 Serum globulins are a heterogenous collection of proteins consisting of  
immunoglobulins  produced by B cells, plasma cells and globulins formed 
chiefly in liver cells. Globulins are increased in conditions of long standing 
hepatic  disease like cirrhosis and chronic hepatitis. In cirrhosis, the increased 
serum gamma globulin concentration is the result of elevated production  of  
Ig (immunoglobulins)  directed against gut bacterial flora. This occurs 
because the cirrhotic liver fails to clear bacterial antigens that normally reach 
the liver through the hepatic circulation. 
 Increases in the concentration of specific isotypes of globulins are 
often helpful in the recognition of certain chronic liver diseases. Diffuse 
polyclonal increases in IgG levels are common in autoimmune hepatitis; 
increases >100% should alert the clinician to this possibility. Raised  IgM 
levels were found in primary biliary cirrhosis, whereas rise  in the IgA levels 
were seen in ethanol induced liver disease. 
Clotting  Factors 
 All clotting factors except factor VIII are synthesized by hepatocytes. 
Factor VIII is produced by vascular endothelium and reticuloendothelial 
cells. The prothrombin time measures the rate of production of thrombin from 
prothrombin. The prothrombin time provides an estimate of hepatic synthetic 
function because it is determined by the activity of the given factors involved 
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in the extrinsic coagulation pathway which includes factors II, V, VII, and X, 
which are all synthesized by the liver. 
 The differential diagnosis of an abnormally prolonged prothrombin 
time also includes vitamin K deficiency, therapeutic anticoagulation, and a 
consumptive coagulopathy. Vitamin K is needed for gamma-carboxylation 
and normal functioning of clotting factors 2, 7,9, and 10. Vitamin K 
deficiency can be associated with malnutrition, malabsorption, or antibiotic 
use and may lead to prolongation of the prothrombin time. The use of 
warfarin interferes with the vitamin K–induced gamma-carboxylation. The 
prothrombin time can be prolonged as a result of disseminated intravascular 
coagulation (DIC) and congenital deficiency of clotting factors. When 
prolongation of the prothrombin time is caused by liver disease, levels of 
factor VIII are normal or increased, whereas in DIC, factor VIII levels are 
decreased. Measurement of the serum factor V level and administration of 
vitamin K can be used to differentiate hepatic dysfunction and vitamin K 
deficiency as a cause of a prolonged prothrombin time. Factor V levels are 
decreased in liver disease but remain unaffected by vitamin K deficiency. 
Administration of vitamin K, 10 mg subcutaneously, results in correction of 
the prothrombin time by at least 30% within 24 hours in patients with vitamin 
K deficiency, but not in those with liver disease. 
 Hepatic synthetic function can be assessed in patients with acute liver  
failure through measurement of the prothrombin time. The level of factor 7, 
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which has a short  half-life (6 hours) when compared to other  factors, can be 
monitored in patients with acute liver failure to assess hepatic synthetic 
function .The international normalized ratio (INR), which is a reproducible 
method used to standardize the monitoring of anticoagulation therapy, is not 
superior as a prognostic indicator to the prothrombin time in patients with 
acute liver failure but has been incorporated into several prognostic scoring 
systems for assessing the severity of liver disease.  
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CONGESTIVE CARDIAC FAILURE 
 It  is a clinical syndrome which may be due to a structural or functional 
defect of the heart causing impairment  of the ventricle to receive or pump 
blood 4.Chronic heart failure is a systemic clinical syndrome which can have 
effects in other organs.The major manifestation includes 
tiredness,breathlessness decreasing the exercise capacity  and features of 
volume overload like pulmonary edema and pedal edema 5. 
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 The overall prevalence of Heart failure in the industrialized countries  
is two in hundred people. Incidence of heart failure rises as the age advances 
affecting nearly five to ten percent  of  population above sixty five years1. 
CHF is widely classified under two groups1,5; 
1. systolic failure (Reduced ejection fraction less than 40%) 
2. Diastolic failure (Ejection fraction preserved more than 40%) 
Etiology 
 Conditions which cause alteration in LV structure or function become 
predisposing factors for a patient to develop HF5. The leading reason for 
cardiac failure  in developed countries in the present times is Ischaemic  
Heart  Disease 
Causes for Systolic Failure(EF less than 40%) 
¾ Ischaemic heart disease      
¾ Myocardial infarction 
¾ Myocardial ischemia 
¾ Obstructive valvular disease 
¾ Regurgitant valvular disease 
¾ Chronic volume overload 
¾ Chronic pressure overloadHypertension 
¾ Hypertension 
¾ Non ischemic dilated cardiomyopathy 
¾ Extracardiac and intracardiac shunting 
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¾ Inherited  disorders  Invasive disorders 
¾ Injury secondary to medications and toxins 
¾ Disorders of Metabolism 
¾ Arrhythmias 
¾ Infections like viral and parasitic causes 
Causes for Diastolic failure (EF More than 40%) 
Diseases causing hypertrophy pathologicaly 
• Primary causes like HOCM(Hypertrophic cardiomyopathies) 
• Secondary causes like Hypertension 
Ageing 
 Conditions causing RCM(Restrictive cardiomyopathy) 
¾ Invading diseases like Amyloidosis and Sarcoidosis 
¾ Metabolic disorders like Hemochromatosis 
• Disorders affecting the Endomyocardium including fibrotic conditions. 
Diseases of pulmonary origin affecting heart 
¾ Cor pulmonale 
¾ Disorders of pulmonary vasculature 
Hyperdynamic circulatory states 
¾ Disorders of metabolism 
¾ Hyperthyroidism 
¾ Disordes of nutrition like Beri beri 
¾ Increased circulatory demands 
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¾ V Shunting 
¾ Anaemia of chronic durati 
PRECIPITATING  CAUSES OF  CCF 
¾ Cardiac arrhythmias 
¾ Pulmonary embolism 
¾ Infections, particularly lung infections 
¾ Rheumatic or viral myocarditis 
¾ Infective endocarditis  
¾ Anaemia  
¾ Conditions with increased metabolic demand like pregnancy, 
thyrotoxicosis 
¾ Acute  myocardial  ischaema or infarction 
¾ Accelerated hypertension 
¾ Acute valvular regurgitation 
¾ Severe physical work or emotional excess increase cardiac workload. 
¾ Improper diet control 
¾ Poor drug compliance 
¾ Drugs worsening failure 
• Calcium channel blockers  
• Beta blockers 
• NSAIDS 
• Monoclonal Antibodies  
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¾  Antiarrhythmic drugs. 
¾ Alcoholism 
In the present study the subjects were considered  as suffering from 
congestive cardiac failure,if they satisfied a minimum of one major and 
minor criteria  based on the FRAMINGHAM CRITERIA for diagnosis of  
heart failure. 
FRAMINGHAM CRITERIA FOR DIAGNOSIS OF HEART 
FAILURE4,5 
Major criteria 
• Paroxysmal nocturnal dyspnea or orthopnea 
• Cardiomegaly 
• Jugular venous distention (or CVP > 16 mm Hg) 
•  Hepatojugular reflex 
• Rales or acute pulmonary edema 
• S3 gallop 
• Response to diuretic (weight loss >4.5 kg in 5 days) 
Minor criteria 
• Exertional dyspnea 
• Nocturnal cough 
• Ankle edema 
• Hepatomegaly 
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• Pleural effusion 
• Vital capacity < two thirds of normal 
• Tachycardia (>120 bpm)  
In this study  symptomatic analysis of the subjects were done and they were 
classified according to the NEW YORK HEART ASSOCIATION  
Classification of Cardiac Failure4,5 into 4 classes. 
NEW YORK HEART ASSOCIATION (NYHA) FUNCTIONAL 
CLASSIFICATION  
Class I  
 No restriction during ordinary actions 
Class II  
 Mild  restriction during ordinary actions 
 Class III  
 Marked  restriction during  normal actions  and  no symptoms at rest  
Class IV  
 Not able to carry out physical activity without symptoms and symptoms can  
be present at rest 
  
PATHOGENESIS 
HF is an advancing  condition  started by an index event leading to injury  to 
the cardiac musculature causing abnormal functioning of cardiac muscle cells 
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or  interrupting  the force producing capability of the myocardium, eventually 
disrupting the normal contracting ability of heart6.  
The inciting  event can  be of sudden onset (like MI) or insidious onset (like 
hemodynamic pressure or volume overload) or inherited ( like genetic 
cardiomyopathies)1,5 .Eventhough they are different in nature, ultimately they 
impair the pumping capacity of heart. 
 
Cardiac failure patients seem to maintain and modify LV function for  
variable time ranging from  months to years by means of  several 
compensatory mechanisms  which get  triggered by the cardiac insult  and   
dysfunction of left ventricle1,4.5. The following compensatory mechanisms are 
called into action  
 (1) The RAA axis (renin-angiotensin-aldosterone)and sympathetic nervous 
system  activation which cause  holding of salt and water  and thus sustaining 
cardiac output  
 (2) raised contractile ability of myocardium.  
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(3) Vasodilating  molecules like the ANP and BNP ( atrial and brain 
natriuretic peptides) PGE2 and PGI2( prostaglandins) and NO (nitric oxide) 
get activated   counteracting  the undue peripheral  vasoconstriction.  
LEFT VENTRICULAR REMODELLING 
Progressive activation of  the above mechanisms produce  a sequence of 
accommodative  alterations  in the myocardium which is  jointly mentioned  
as LV remodeling eventually leading to the  evolution to symptomatic 
failure5,6. 
 A succession of intricate events happen in  molecular and cellular stages 
during remodeling of LV1,5. The factors stimulating  these changes are 
¾ Muscle fibre subjected to  mechanical stretching 
¾ Neurohormones in circulation (like noradrenaline, angiotensin II) 
¾ Inflammatory cytokines [like TNF ( tumor necrosis factor) ] 
¾ Growth factors and Peptide hormones (like  endothelin) 
¾ Oxygen free radical species (like  superoxide and NO).  
The persistent activation of  this  molecules leads  to advancement  of  heart 
failure by means of the harmful effects they produce on the heart and blood 
vessels .  
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TYPES OF CARDIAC FAILURE  
 Heart failure may be acute or chronic, left-sided or right-sided, high-
output or low-output, forward or backward, and systolic or diastolic5. 
Acute  and  chronic failure 
  The main characteristic feature of  acute heart failure is it  occurs 
suddenly subsequent to a large myocardial infarction or heart  valve rupture . 
Here  there is  an acute fall in cardiac output leading to hypotension .There is 
absence of extremity oedema4. Chronic heart failure occurs in the context of  
gradually progressive  dilated cardiomyopathy,  valvular  heart disease and 
systemic hypertension. Blood pressure is well preserved in chronic heart 
failure but usually extremity oedema is present 30. 
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Left-sided  and  right-sided failure 
  Left sided heart  failure is characterized by  pulmonary congestion 
causing dyspnoea and orthopnoea. Usually occurs in conditions when there is 
a pressure  overload on  LV as in aortic stenosis or it is weakened due to a 
myocardial infarction1. Right-sided failure presents with features of  systemic 
congestion  which include  elevated  jugular venous pressure, congestive liver 
enlargement  and lower extremity oedema. In long- standing cases of cardiac 
failure like valvular heart disease (aortic and mitral valve) and hypertension,  
features  of  biventricular   failure are present4. 
High-output failure and Low- output failure   
 High-output failure is encountered in severe anaemia, thyrotoxicosis, 
beriberi, arterio-venous fistulae, pregnancy  and Paget’s disease. The heart 
has to deliver excessive amount  of  blood to provide sufficient supply of 
oxygen to the highly metabolically active tissue in these conditions6. Low 
output failure is seen conditions like coronary artery disease, dilated  
cardiomyopathy ,  hypertension , pericardial and valve diseases of heart.    
Forward  and backward failure  
 Backward heart failure is featured by elevated  pressure and volume in 
the atrium and systemic veins proximal to the failing ventricle  producing 
sodium and water  retention causing development of  oedema.  Forward heart 
failure is described based on the  insufficient cardiac output  as a result of left 
ventricular systolic dysfunction.This  results  in decreased renal blood flow 
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causing stimulation of  the RAAS(renin-angiotensin-aldosterone system) with 
concomitant retention of salt and water producing oedema 4,5,6.  
Systolic and diastolic failure  
 Systolic heart failure is featured by   principal systolic ventricular 
contractile dysfunction chiefly due to myocardial dysfunction leading to an 
inadequate output and further symptoms. The main aetiologies include dilated 
cardiomyopathy , ischaemic heart disease,  chronic excessive ventricular 
workload as in systemic hypertension, valvular heart disease (like  mitral 
incompetence, aortic stenosis, aortic incompetence) and congenital heart 
disease (like ventricular septal defect, coarctation of aorta, congenital 
pulmonary and aortic stenosis). 
 Diastolic heart failure is characterized by lack of relaxation of ventricle 
causing rise of  diastolic pressure in the ventricle  and preserved   diastolic 
volume. The commonest cause of diastolic dysfunction  is ischaemic heart 
disease . Increased stiffness and thickening of  ventricle as seen in restrictive 
cardiomyopathy due to amyloidosis or haemochromatosis  also produces 
diastolic dysfunction . 
In most patients with cardiac hypertrophy and dilatation, systolic and 
diastolic heart failure co-exist 
 Diastolic Heart Failure 
¾ Small LV cavity, concentric LV hypertrophy 
¾ Systemic hypertension 
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¾ Elderly women more common 
¾ Normal or increased ejection fraction 
¾ S4 gallop 
¾ Diastolic impairment by various echo measurements 
¾ Treatment not well established 
¾ Prognosis not as poor 
¾ Myocardial ischemia common 
Systolic Heart Failure 
¾ Large, dilated heart 
¾ Normal or low blood pressure 
¾ Broad age group; more common in men 
¾ Low ejection fraction 
¾ S3 gallop 
¾ Systolic and diastolic impairment by echo 
¾ Treatment well established 
¾ Poor prognosis 
¾ Role of myocardial ischemia important  
Clinical Manifestations   
 The chief symptoms of HF are fatigue and shortness of breath. 
Although fatigue is thought to be due to the low cardiac output in HF, it can 
also be contributed by skeletal-muscle abnormalities and other non-cardiac 
co-morbidities30 . In  initial  stages of cardiac decompensation ,  exertional 
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breathlessness is present , as failure advances lower levels of activity causes 
dyspnea and eventually progressing to dyspnea at rest. It has a multi-factorial 
origin which  include pulmonary fluid collection , rising  airway impedance 
,declining lung compliance , anemia and breathing muscle fatigue. Dyspnea 
may become less frequent with the onset of right ventricular (RV) failure and 
tricuspid regurgitation22. 
Orthopnea   
 Orthopnea or dyspnea in  lying down posture is late feature of failure. 
The cause is increased venous return  to the heart  in supine position leading 
to an increase in pulmonary capillary pressure which stimulates the juxta-
capillary J receptors resulting in dyspnea. Nocturnal cough is the most 
frequent and common symptom. It is relieved by maintaining an upright 
posture. Also seen in conditions other than cardiac disorders. 
Paroxysmal Nocturnal Dyspnea (PND) 
 It is the development of  sudden onset of severe breathlessness  and 
coughing happening usually at night-time usually 1–3 h after the patient 
retires to bed. It can be easily deduced from the history given by the patient 
which he describes as if he is awakened after a few hours of sleep by the 
shortness of breath and he gasps for air by standing near the window. PND 
manifests by coughing or wheezing and is due to increased pressure in the 
bronchial arteries causing compression of the airway which along with 
interstitial pulmonary edema leading to increased airway resistance. Patients 
 
 
37 
 
with PND continue to have symptoms even after assuming the erect position 
which differentiates it from orthopnea. Cardiac asthma is characterized by 
wheezing secondary to bronchospasm, and must be differentiated from 
primary asthma and pulmonary causes of wheezing. 
Cheyne-Stokes Respiration  
 Cheyne-Stokes breathing  is usually associated with low cardiac 
output. It is produced by a decreased  stimulation  of the central respiratory 
region to elevated arterial CO2 .It has the following phases: An apneic phase 
in which the there is a fall in the arterial PO2 and a corresponding rise in 
PCO2 which sensitizes the respiratory centre followed by hyperventilation 
and decrease in   PCO2  levels which constitutes the hyperpneic phase. It is 
described as a brief cessation  of breathing by the subject.    
Other Symptoms   
 Patients with HF may also present with gastrointestinal symptoms. 
Symptoms associated with congestion of gut wall and liver are loss of 
appetite, nausea, early fullness and abdominal pain . Right upper quadrant 
pain may occur due to stretching of capsule because of congestive 
hepatomegaly. Cerebral symptoms, which may be due to cerebral 
arteriosclerosis or reduced cerebral perfusion  like confusion and mood 
changes may occur predominantly in elderly subjects. 
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Physical Examination  
General Appearance and Vital Signs  
¾ In mild to moderate  HF, the patient is comfortable at rest,with 
symptoms of orthopnoea 
¾ In more severe HF, the patient  dyspnoeic  in siting posture . 
¾ Decreased  pulse pressure  
¾ Systolic BP may be normal ,high or low according to the severity of 
cardiac failure 
¾  Sinus tachycardia 
¾  Cool peripheries , cyanosed lips and nails  due to vasoconstriction 
¾ Elevated  Jugular Venous pressure 
¾ Presence of hepatojugular reflex  
Pulmonary Examination  
• Pulmonary crackles due to the transudation of fluid from the 
intravascular space into the alveoli 
• Expiratory wheezing (cardiac asthma) 
•  Pleural effusions result from the elevation of pleural capillary pressure 
and the resulting transudation of fluid into the pleural cavities.  
a) pleural effusions occur commonly with biventricular failure.  
b)  pleural effusions are often bilateral in HF, when unilateral they occur 
more frequently in the right pleural space.  
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Cardiac Examination  
¾ Cardiomegaly  with shifted  apical impulse. A sustained apical impulse  
due to severe LV hypertrophy  
¾ A third heart sound (S3) is audible and palpable at the apex due to 
volume overload  
¾ A sustained and prolonged left parasternal heave due to hypertrophied 
right ventricle.  
¾ A fourth heart sound (S4) present diastolic dysfunction.   
¾ The murmurs of mitral and tricuspid regurgitation heard in patients 
with advanced HF. 
Abdomen and Extremities  
¾ Tender  hepatomegaly  
¾ Pulsatile liver in systole in tricuspid regurgitation. 
¾ Ascites  
¾ Jaundice also occurs late with elevations of both direct and indirect 
bilirubin.  
¾ Peripheral edema is usually symmetric and dependent in the ankles and 
pretibial region in ambulatory patients 
¾  presacral edema  and the scrotal edema in bed ridden cases.  
Cardiac Cachexia  
• Marked weight loss and cachexia. 
• Signifies a poor  prognosis. 
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Diagnosis  of Heart Failure 
 Laboratory  Investigations  
 Subjects presenting with acute heart failure or exacerbation of chronic 
heart disease should undergo the following regular laboratory investigations. 
These include 
• Complete blood count 
• Renal function tests 
• Serum electrolytes 
• Liver function tests  
• Urine analysis .   
• Evaluation for DM(Diabetes Mellitus) which includes fasting blood 
glucose,post prandial glucose  and in some cases OGTT(Oral glucose 
tolerance test) 
• Fasting lipid profile to rule out dyslipidaemia 
•  Thyroid function tests including TSH(Thyroid stimulating hormone) 
 Electrocardiogram  
¾ A regular twelve -lead Electrocardiogram (ECG ) is mandatory.    
¾ To rule out left ventricule enlargement, arrhythmias, presence of old 
myocardial infarction.  
A normal ECG virtually excludes LV systolic dysfunction. 
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Chest X-Ray  
¾ To rule out cardiomegaly  
¾ To assess the pulmonary vasculature,  
¾ To find out any  noncardiac reasons  
¾  Acute cases of  cardiac failure  show findings of  pulmonary artery 
dilatation  and features of  pulmonary congestion. 
¾  Long standing cases of cardiac failure often lack the above 
radiological findings. This may be accounted by the improved 
lymphatic drainage of fluid in lungs. 
Left ventricular function Evaluation 
9 The identification ,assessment  and treatment of  cardiac failure 
requires Non-invasive  cardiac imaging . 
9 The most valuable investigation  is Two-D Echo or Doppler 
9  It   delivers  a  semi-quantitative evaluation of  
a)  Left ventricular  dimensions and  function  
b)  To find out  valvular lesions 
c) To identify  RWMA(regional wall motion abnormalities) which 
suggests an old MI. 
d)  To look for Left atrial enlargement and Left ventricular enlargement 
9 Tissue and  Pulse-wave Doppler  beneficial for evaluation of heart 
failure with  EF more than 40%  and to identify LV Diastolic 
dysfunction.  
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9 Presently MRI  is  the gold standard for evaluating LV dimensions and 
capacities giving  a complete study of  structure and function  of heart.  
9 The best valuable guide to assess LV performance  is  Ejection 
Fraction(EF).        Ejection Fraction=Stroke volume/ End-diastolic 
volume. 
9  Ejection Fraction(EF)  is convenient  to calculate using non-invasive 
methods and simple to understand.    
9 The major shortcoming of EF is it is easily affected by  variations in 
end diastolic volume and vascular resistance. 
Biomarkers  
¾ Natriuretic peptides  in circulation are valuable markers in identifying  
people with HF. 
¾ B-type natriuretic peptide (BNP) and N-terminal pro-BNP  are fairly 
sensitive indicators for detecting  heart failure  with depressed EF 
¾ A lesser degree of elevation noted in heart failure cases with 
maintained EF.  
¾   Levels of Natriuretic peptide rise  with age and kidney damage. 
¾ Additional  Biomarkers are 
a)  Troponin T and I 
b)  C-reactive protein 
c) TNF receptors 
d)  Uric acid  
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Exercise Testing  
 Treadmill or bicycle exercise testing valuable  for evaluating  the 
requirement of  heart transplantation in severe advanced HF . 
 A greatest oxygen uptake (VO2) <14 mL/kg / min was found to have a 
bad prognosis. 
 Cases with VO2<14 mL/kg /min were found to have prolonged survival   
with transplantation . 
Differential Diagnosis 
 Following conditions  should be considered in differential diagnosis of  
cardiac failure   
 (1)  Kidney Failure  
 (2) Noncardiogenic pulmonary congestion  like ARDS( acute respiratory 
distress syndrome).  
 The diagnosis of cardiac failure is direct in the presence of typical 
clinical features. But at times there may arise difficulty in differentiating 
cardiac dyspnoea  from respiratory causes. In   such  situations  noninvasive 
cardiac imaging, biomarkers, pulmonary function testing  become valuable. 
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NORMAL HEPATIC ARCHITECTURE 
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MECHANISM  OF  HEPATIC DYSFUNCTION  IN  HEART  
FAILURE 
Heart   failure causes: 
a) reduced liver blood supply 
b) elevated hepatic venous pressure  causing swelling of sinusoids and 
atrophy of liver cells. 
 In cardiac failure there is elevated venous back pressure which is 
transferred to the hepatic veins and results in congested liver22.Another major 
factor causing injury is hypoxia23. Histological analysis shows atrophy of liver 
cells in zone 3 is caused by raised pressure24.  
 Raised venous pressure in the sinusoids cause widening of sinusoidal 
pores leading to leakage of fluid into perisinusoidal  space 25.This edema 
decreases transport of nutrients and oxygen to the  liver cells24. Usually this 
fluid drains into lymphatics ,when there is excess fluid more than the 
drainage ability of lymph channels this fluid with excess protein content 
collects in the peritoneal cavity and produces ascites26. When the congestion 
becomes chronic fibrosis ensues in zone 3 ,surrounding the veins and 
perisinusoidal space and reduce transfer of nutrients to liver cells. Long  
standing venous stasis can promote thrombus formation  in sinusoids and 
venules which has fibrogenic  tendency leading to regional fibrosis in liver.   
Reduced  blood  supply  to  liver   is also important in causing  necrosis of 
cells  as observed  by Sherlock et al .Wanless et  al  as described in their 
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study  that  acute  left  heart  failure led to necrosis of  zone 3 liver cells in the 
absence of right heart failure showing that cardiac output is a major factor 
causing hepatic injury. Still congestion appears to be a cofactor in hepatic 
injury. It plays an important role in preparing the liver sensitive to ischaemic 
insults. 
Liver ischaemia 
 Disparity between liver oxygen supply and need leads to liver 
ischaemia. As liver has a constant metabolism ,oxygen delivery is the major  
determinant  of liver ischaemia26.Oxygen supply  to liver  depends on the 
hepatic blood flow and oxygen content of blood. It has been shown that 
cardiac output determines the blood supply to the liver .Hepatic blood supply 
is dual .Liver receives 20% of blood supply from hepatic artery and 80% 
from portal vein,hence major oxygen supply is from the portal vein. 
With exercise  usually cardiac output  increases  but  in diseased   heart 
cardiac output fails to rise and there is a fall in hepatic blood supply.In the 
normal state liver cells compensate by increasing the oxygen extracted.But in 
conditions of stress  liver metabolic demands increase  and oxygen extraction 
cannot be increased above a limit leading to liver cell hypoxia in the zone 3 
of acini 27.   
 Observation in animals show that liver cells are susceptible to reduced 
oxygen supply at  physiological  temperatures due to increased metabolism 
than other liver cell types28. Nutrition also plays significant role in 
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determining  liver cell sensitivity to hypoxia . Ishaemia  to liver cell causes 
damage to mitochondria ,decrease in ATP,increase in intracellular calcium 
and protease activation 29. Reperfusion injury also causes damage to liver 
cells by formation of free radicals  and lipid peroxidation. 
 In the damaged mitochondria reactive oxygen species are formed 
which has direct toxic effect on the cells.Reperfusion  causes transcription of 
numerous genes in liver cells that produces factors and various cytokines 
leading to liver cell damage .  
.  
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HIOSTOPATHOLOGY OF LIVER IN CONGESTIVE HEART 
FAILURE 
Macroscopic appearance 
 
 In congestive heart failure  the size of liver is enlarged  ,surface is 
smooth and the edges are rounded with purple coloured appearance.Cut 
section of liver shows venous engorgement with characteristic nutmeg 
appearance 7. The pale periportal region is seen alternating with the dark 
brown centrilobular region. In later stages when cardiac fibrosis ensues the 
capsule becomes granular and uneven. Cross section of liver revealing ill 
defined granular parenchyma and presence of nodules in the periportal 
regions9 .The size of  nodules being  less than 1-2 mm.When compared to 
true cirrhosis nodular size is less , ill defined, non uniform distribution and 
situated in the periportal regions7 . 
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Microscopic appearance 
 
 Liver in cardiac failure shows microscopic features of congestion and 
necrosis in zone3 .In initial stages of congestion the zone 3 liver cells are 
flattened and atrophic and the nearby sinusoids are filled with blood. As the 
severity of congestion increases  more significant  atrophic changes are noted 
with further extension into the veins9 .Hepatocytes in centrilobular zone 
shows  large concentrations of brown pigment. 
 Later on there is development of fibrosis across the central veins . 
Reduction in cardiac output and decreased blood flow  leading to hypoxia is 
main reason for zone 3 necrosis.It has been reported that necrosis can occur 
 
 
50 
 
even without shock or hypotension.An associated  inflammatory reaction is 
noted with presence of lymphocytes ,neutrophils and plasma cells. 
 Peripheral zones show a rise in the liver cells leading to degenerative 
hyperplasia. This causes liver cell plate thickening. The cells are large with 
pale cytoplasm and pleomorphic nuclei. Certain cases show nodular 
hyperplasia. 
 The predominant histological features are central portal fibrosis with 
early nodularity in the parenchyma. Cardiac cirrhosis is reported to be a rare 
occurrence21.  
 
Hepatic Congestion: 
 There is dilatation of the central veins, sinusoids and peri-sinusoidal 
space leading to pressure atrophy of the liver cells which eventually necrose 
producing central hemorrhagic necrosis. Ischemic mechanisms can also need 
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to necrosis. Fatty changes are also seen in certain liver cells. Zone 3 
hepatocytes show a light brown pigment which is lipochrome23. 
CLINICAL FINDINGS IN CONGESTIVE HEPATOPATHY: 
 Most leading cause of congestive heart failure producing liver 
abnormalities in the developed world is coronary artery disease. Incidence of 
hypertension is also increasing. Rheumatic heart disease leading onto cardiac 
failure which was previously more common has declined. Other uncommon 
causes are cor pulmonale, cardiomyopathies and congenital heart diseases. 
Hepatic abnormality in cardiac failure is usually asymptomatic and mild. 
Routine liver function tests may show abnormality in these patients. 
Clinically patients can have right hypochondrial pain due to enlargement of 
liver and stretching of the capsule. Other symptoms like anorexia, vomiting 
can also occur11,12. Usually acute heart failure or exacerbation of chronic 
heart failure presents with such symptoms. 
Physical Examination: 
 Jaundice is reported in nearly 20% of patients with congestive 
hepatopathy. Hepatomegaly is noted in 90-95% of patients presenting with 
severe cardiac failure. The liver may be enlarged upto 5 cm beneath the costal 
margin in nearly 50% of the subjects. JVP is elevated and hepato-jugular 
reflex can be seen. Pulsatile liver can be visualized in cases with tricuspid 
insufficiency. Ascites is observed in approximately 10-40% of the cases. 
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Pedal edema and pleural effusion  has also been reported in patients with 
right heart failure. 
  
LIVER BIOCHEMICAL ABNORMALITIES IN HEART FAILURE 
Serum Bilirubin: 
 A wide range of liver function abnormalities has been noted in 
congestive cardiac failure. Nearly 75% of patients show a slight elevation in 
serum bilirubin values. Usually it does not exceed 3mg/dl and the indirect 
fraction is more than direct fraction. Factors producing this rise include liver 
cell dysfunction, RBC lysis, pulmonary infarction, infections and drugs. 
Sherlock et al observed a relation between right atrial pressure and serum 
bilirubin in his study. Hence the jaundice in right heart failure occurs 
predominantly due to congestion than ischemia. With the control of failure 
the bilirubin values become normal in a period of 1 week. 
Serum Transaminase:  
 These enzymes show a rise in congestive cardiac failure. AST and 
ALT show an increase in nearly 30% of cases whereas LDH was found to be 
increased in 50% of cases. 
 Reduced liver blood supply and venous congestion lead to increase in 
transaminases, however the predominant factors are hypoxia and necrosis. In 
a study of 175 cases with both acute and chronic failure, AST showed a 
predominant increase in acute heart failure than chronic cases. The values 
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were in the range of 40-90 IUs. The rise in ALT values were less significant. 
In cases of acute severe cardiac failure with hypotension and shock, AST 
levels as high as 1000-10000 IUs were reported. The rise in AST, ALT and 
LDH is in accordance with the rise in venous pressure, PCWP (pulmonary 
capillary wedge pressure) and cardiac output.  
 A recent occurrence of acute heart failure, already existing chronic 
heart failure and early onset of renal dysfunction suggest that hepatic 
dysfunction is due to circulatory failure and not due to viral or drug induced 
causes. 
Serum Alkaline phosphatase:  
 In most cases of cardiac failure, ALP levels are within normal range. In 
certain studies an elevation of 10-20% has been reported. The rise in ALP 
values shows no relation with serum bilirubin or transaminases. In cases with 
massive hepatomegaly high values have been observed. Hence intrahepatic 
blockade secondary to congestion is considered to be the cause for abnormal 
levels. With the control of cardiac failure raised values become normal in 
nearly 1 week. 
Serum proteins: 
 In congestive hepatomegaly 30-50% of patients were reported to have 
reduced serum albumin levels. This reduction showed no correlation with the 
duration of cardiac failure. The values were in the range of 2.5-2.9 g/dl. The 
causes for decreased albumin in cardiac failure are reduced synthesis, 
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reduced absorption and poor nutrition. The values rarely go below 1.5 g/dl. 
The correction in serum albumin following control of cardiac failure takes a 
few months. 
 Increase in globulin was observed in 40-60% of cases with right heart 
failure. It is more common in acute rather than chronic failure. Usually a mild 
rise noted with values ranging from 3.5-4.1 g/dl in most of the cases. This 
increase was not found to return to normal even after control of heart failure. 
Prothrombin time:  
 It is a sensitive marker of right heart failure as it was found to be 
prolonged in nearly 90% of subjects with congestive hepatomegaly due to 
cardiac failure. This prolongation may be due to reduced liver production or 
decreased Vitamin K dependent activation of clotting factors. Following 
treatment of right heart failure it takes two to three weeks for the resolution of 
prothrombin time. 
 Long-standing and recurrent congestive cardiac disease can produce 
cardiac cirrhosis. However the incidence is very low as most patients 
succumb to cardiac illness before the onset of cirrhosis. 
REVIEW OF JOURNALS AND PAPERS 
 Liver  enlargement is considered as one of the common presentation of 
congestive cardiac failure. A large number of studies on liver function  have 
been conducted by many investigators to assess the extent of liver damage in 
heart failure.  
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It was Kierman29 who first found an association between pathology of liver 
and congestive cardiac failure.He was the one who elaborated the term 
nutmeg liver.Later on after nearly seventy years Mallory gave the description 
of the characteristic microscopic appearance of congested liver with focal 
necrosis and centrilobular congestion13. Investigators like Lambert et al , 
Zimmerman et al observed the fatty alterations and exudation of fluid into 
pericapillary space causing pressure over the capillaries15,19. 
 In cardiac failure patients the biochemical and pathological findings of 
necrosis in zone 3 of hepatic acini was elaborated  by Sherlock et al 12.. 
Subjects suffering  from severe cardiac failure were found to have elevated 
bilirubin levels by Cantarow  and Jolliffe et al who observed reduced 
clearance of bromsulfalein from circulation in cardiac failure cases12,14. 
Studies conducted in Montefiore medical centre also reported similar 
observations. Cardiac failure cases showed a three fold increase in the fibrotic 
changes in liver when compared to cases without cardiac decompensation. 
Gravin et al has reported cases of cardiac cirrhosis in autopsy findings of 
patients whose principal cause of death was heart failure21. 
Studies conducted by Rich et al , Libman et al reported increased incidence of  
jaundice  in cardiac failure secondary to pulmonary embolism and infarction 
18,20. Other theories proposed in the pathophysiology of hepatic dysfunction 
include presence of sepsis as observed by Mallory et al13, hypoxia occurring 
due to lack of  nutrition as noted by Keefer et al17 and  Jaffee et al16 studied 
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the role of compression on liver dysfunction. Killip et al reported in his study 
the enormous rise in serum aminotransferases in cases with shock36. All the 
above data point towards the association between liver function abnormalities   
and heart failure.  
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MATERIALS AND METHODS 
PLACE OF STUDY  
  This study was conducted in the  General Medical wards and Intensive 
care unit of Tirunelveli Medical college hospital,Tirunelveli.  
PERIOD OF STUDY  
 November 2011 to November 2012.  
DESIGN OF STUDY  
 This study is a Single Centre Cross-Sectional and Analytical Study. A 
total of 60 subjects were included in this  study. 
METHODOLOGY 
A) SUBJECT SELECTION 
1) Inclusion criteria 
 1.Congestive cardiac failure in all age groups of varying etiologies 
2) Exclusion Criteria  
 1. History of alcoholism.  
 2. Past history of jaundice.  
 3. Recent intake of hepatotoxic and cholestatic drugs.  
 4. Presence of viral markers 
 5. Blood transfusion.  
 All subjects included in this study were subjected to thorough clinical 
examination. All were subjected to laboratory investigations as per the 
proforma. 
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The following liver biochemical tests were carried out in this study: 
1. Serum bilirubin 
2. Serum transaminases  
3. Serum alkaline phosphatase 
4. Serum proteins 
5. Prothrombin time 
Serum Bilirubin: 
 Estimation of serum bilirubin was done by the Wandenburg reaction. 
In this test the bile pigments are diazotized by the sulphalinic acid and the 
products are estimated calorimetrically. This reaction can also differentiate 
indirect and direct fractions due to the differing solubilities of these fractions. 
The water soluble direct fraction produces the direct VB reaction when 
carried out in an aqueous medium. In ethanol the intramolecular hydrogen 
bonds of indirect bilirubin are fragmented and both direct and indirect 
fragments show reaction giving the total bilirubin value. The direct bilirubin I 
subtracted from the total bilirubin to get the indirect bilirubin value. 
Serum enzyme assays: 
Serum AST and ALT: 
 In this study AST and ALT was measured by enzymatic substrate 
method. AST and ALT substrates along with dinitro phenyl hydrannel were 
used. The enzyme catalyses the exchange of gamma amino group of alanine 
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to the gamma keto group of glutamate forming oxalo-acetic acid and pyruvic 
acid. 
Serum ALP: 
 A variety of assays have been developed to measure alkaline 
phosphatase using different substrates. The substrates used were 
aminoantipyrine solution, alkaline phosphate buffer, potassium ferricyanide 
and substrate. Increased levels of ALP shows biliary tract dysfunction. Slight 
to moderate elevation in ALP activity can occur in congestive cardiac failure. 
The raised levels signify rise in the synthesis of ALP by liver cells and biliary 
epithelium. 
Serum Proteins: 
 Widespread hepatic damage leads to reduction in serum levels of 
fibrinogen, prothrombin, albumin and other proteins which are produced 
exclusively by the liver cells. The estimation of serum proteins signify 
hepatic synthetic function. The most major protein synthesized by the liver is 
albumin. Normal level ranges from 3.5-5.5 mg/dl. It has a long half-life i.e 
14-20 days and daily turn-over is less than 5%. Hence it is not an accurate 
indicator of acute hepatic damage. 
 Serum globulins include alpha and beta globulins as well as 
immunoglobulins. Normal value is 2-3.5 mg/dl. Hyperglobulinemia occurs 
secondary to activation of the reticulo-endothelial system in response to the 
antigens presented passing through the liver. 
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Serum proteins are estimated by Biuret method. Substances which contain 2 
or more peptide bonds and CO-NH2 groups give a purple or blue coloured 
precipitate with alkaline copper solution. Different proteins give differing 
amount of colour which helps in distinguishing them by this reaction. 
Prothrombin time: 
 Clotting factors like fibrinogen, factor 2,5,7,9,10 are synthesized in the 
liver. Any dysfunction of the clotting factors can be determined by one stage 
prothrombin time. This method calculates the conversion rate of prothrombin 
to thrombin in the presence of calcium and thromboplastin. This reaction 
requires properly functioning Vitamin K dependent clotting factors. These 
clotting factors have a short half-life, hence prothrombin time can be taken as 
an earlier marker of hepatic injury and its prolongation in both acute and 
chronic hepatic damage signifies worse prognosis. 
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NORMAL VALUES OF LIVER FUNCTION TESTS 
 
SL NO LIVER FUNCTION TESTS NORMAL VALUES 
1. Serum BILIRUBIN 0.3 – 1.2mg/dl 
2. Serum AST/SGOT 0 – 40 I.U 
3. Serum ALT/SGPT 0 – 35 I.U 
4. Serum ALP 20 – 140 I.U 
5.  Serum  TOTAL PROTEINS 6 – 8.5 g/dl 
6.  Serum ALBUMIN 3.5 – 5.5 g/dl 
7. Serum GLOBULIN 2.5 – 4.5 g/dl 
8. PROTHROMBIN TIME 
12 – 14 sec (control) 
abnormal if >1.5 times 
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OBSERVATION AND ANALYSIS 
TABLE 1 - AGE DISTRIBUTION OF THE CASES 
              Age group 
of the cases in 
years  
Frequency of cases in 
each age group 
           percentage 
 
26-35 7 11.7
36-45 9 15.0
46-55 19 31.7
56-65 21 35.0
66-75 4 6.7
Total 60 100.0
                                 
AGE DISTRIBUTION 
 
 
 
 Out of 60 subjects studied  19 cases belonged to the age group 46-
55yrs and 21cases belonged to the age group of 56-65 yrs  showing the rising 
prevalence  of cardiac disease  with advancing age. 
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TABLE 2 
SEX DISTRIBUTION OF THE CASES 
  
Gender group of 
cases 
Frequency of cases in 
each group 
Percentage 
 
Male 41 68.3 
Female 19 31.7 
Total 60 100.0 
                                      
 
SEX DISTRIBUTION OF CASES 
 
 
 In this study 60 subjects were chosen randomly,of these  41 were males 
which is 68.3% and 19 were females which is 31.7% suggestive of the rise in 
cardiac diseases and failure in male population. 
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TABLE 3 
ETIOLOGY OF CARDIAC FAILURE 
 Etiology of failure Frequency of cases Percentage 
Coronary artery disease 23 38.3 
Cor Pulmonale 14 23.3 
Rheumatic heart disease 10 16.7 
Cardiomyopathy 6 10.0 
Hypertensive heart disease 7 11.7 
Total 60 100.0 
 
ETIOLOGY OF CARDIAC FAILURE 
 
  Maximum number of cases( 38.3%) came under the category of 
Coronary Artery Disease  followed  by Cor pulmonale  (23.5%).   This shows 
that  Coronary artery disease  is  emerging has the single most  common 
cause of cardiac failure. The incidence of  Rheumatic Heart Disease which 
was previously considered as leading cause of heart failure has declined. 
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TABLE 5  
DURATION OF CARDIAC FAILURE 
Duration  of cardiac 
failure 
Frequency in 
each group 
Percentage 
 
<1 1 1.7 
1-5 35 58.3 
>5 24 40.0 
Total 60 100.0 
 
 
 Of the 60 subjects studied ,the duration of illness is between 1- 5 years 
in 35 cases ,less than 1 year in 1 case and more than 5 years in 24 cases. 
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TABLE 4 
CASE  DISTRIBUTION  ACCORDING  TO  NEW YORK HEART 
ASSOCIATION CLASS  OF  HEART  FAILURE 
NYHA class of 
heart failure 
Frequency of cases in 
each class 
Percentage 
 
Class I 17 28.3 
ClassII 22 36.7 
Class III 12 20.0 
Class IV 9 15.0 
Total 60 100.0 
  
 
 
 
 
 
 
 
 Of the total 60 subjects 17 cases belonged to class1 ,22 cases belonged 
to class2,12 belonged to class3 and 9 belonged to class 4.This suggests the 
improvement in the control of failure symptoms with the currently available 
therapy. 
 
 
 
67 
 
TABLE 6 
PRESENCE OF CLINICAL JAUNDICE IN THE CASES 
Presence of  
jaundice 
Frequency Percentage 
Present 20 33.3 
Absent 40 66.7 
Total 60 100.0 
 
 
 
 Clinical Jaundice was detected in 20 cases which constitute 33.3% and  
the rest were found to be normal which correlates with the pbservation of  
Biegus et al. 
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TABLE 7 
PRESENCE OF HEPATOMEGALY IN THE CASES 
Presence of 
Hepatomegaly 
Frequency Percent 
Present 25 41.7 
Absent 35 58.3 
Total 60 100.0 
 
 
 
 
  Out of 60 cases studied clinically hepatomegaly was found  in 25 
cases  which forms 41.7%  which is in accordance with the observations of 
Sinha et al and Richman et al11. 
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TABLE   8 
PRESENCE OF ASCITES IN THE CASES 
Presence of  
Ascites 
Frequency Percent 
Present 7 11.7 
Absent 53 88.3 
Total 60 100.0 
 
 
 Ascites was clinically made out in 11.7% of cases studied which 
correlates with findings of Norman et al12. 
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TABLE  9  
ULTRASOUND ABDOMEN  SHOWING  CONGESTIVE     
HEPATOMEGALY  IN  THE  CASES 
USG Abdomen with 
congestive liver 
Frequency 
 
Percent 
 
Present 23 38.3 
Absent 37 61.7 
Total 60 100.0 
 
 
 Ultrasound scanning of the abdomen was done in all the 60 cases to 
identify congestive liver.Of these 23 cases showed abnormality in USG 
Abdomen(38.3%).   
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TABLE 10 
LIVER BIOCHEMICAL ABNORMALITIES NOTED IN THE STUDY 
GROUP 
Serum Bilirubin Frequency Percent 
Abnormal 34 56.7 
Normal 26 43.3 
Total 60 100.0 
 
LIVER 
PARAMETERS 
Abnormal Normal 
FREQUENCY  PERCENT FREQUENCY         PERCENT 
Serum  
Bilirubin 
34 56.7 26 43.3
Serum  AST 32 53.3 28 46.7
Serum  ALT 37 61.7 23 38.3
Serum  ALP 8 13.3 52 86.7
Serum  Total 
Protein 
12 20.0 48 80.0
Serum Albumin 23 38.3 37 61.7
Serum Globulin 4 6.7 56 93.3
Prothrombin 
Time 
21 35.0 39 65.0
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 Serum Bilirubin  were found to be abnormal  in 56.7% of  the total 
congestive cardiac failure patients included in this  study.Serum AST was 
found to be abnormal in 53.3% of the subjects and serum ALT was abnormal 
in 61.7% of the cases whereas serum ALP was found to be abnormal   only in 
13.3% of cases  thus suggesting a hepatocellular pattern of liver enzyme 
elevation. Serum albumin was found to be decreased in 38.3 % of the 
subjects  and serum globulin was abnormal in 6.7% of cases. Prolongation of 
prothrombin time was observed in 35% of cases. 
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TABLE  11 
PREVALENCE OF LIVER FUNCTION ABNORMALITY IN THE      
STUDY GROUP 
LIVER FUNCTION 
TESTS 
Frequency Percentage 
Abnormal 34 56.7 
Normal 26 43.3 
Total 60 100.0 
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TABLE 12 
SHOWING COMPARISON OF MEAN BILIRUBIN VALUES WITH  
NYHA CLASS OF CARDIAC FAILURE 
NYHA 
CLASS 
FREQUENCY 
Mean 
BILIRUBIN
S D F p value 
Class I 17 1.1 .2  
58.555 
 
 
 
 
<0.001 
 
 
 
ClassII 22 1.5 .4 
Class III 12 2.3 .5 
Class IV 9 2.9 .5 
Total 60 1.7 .8 
  
 
 P value less than 0.001 is significant thus suggesting a progressive 
increase in mean serum bilirubin values with worsening of heart failure class. 
Class 4 patients showed marked liver function  abnormality.  
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TABLE 13 
SHOWING  COMPARISON  OF MEAN AST VALUES WITH NYHA 
CLASS OF HEART FAILURE 
NYHA 
CLASS 
FREQUENCY
Mean AST 
VALUES 
S D F p value 
Class I 17 36.9 3.5 
 
5.171 
 
0.003 
ClassII 22 39.9 5.4 
Class III 12 87.5 41.7 
Class IV 9 188.8 271.8 
Total 60 70.9 115.0 
  
 
This table shows a sequential rise in serum AST levels with advancement of 
cardiac failure. p value is 0.003 which is  significant . 
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TABLE 14 
SHOWING   COMPARISON OF DIFFERENT  LIVER 
PARAMETERS  WITH  NYHA  CLASS  OF  HEART  FAILURE 
Liver function tests Nyha class  
Frequency in 
each class 
Mean 
values      S D F p value 
Serum  ALT  
  
  
  
  
Class I 17 32.4 4.0 5.933
  
  
  
  
.001
  
  
  
  
ClassII 22 34.9 6.0 
Class III 12 81.0 34.5 
Class IV 9 142.0 186.2 
Total 60 59.5 80.7 
Serum  ALP  
  
  
  
  
Class I 16 44.3 10.8 .336
  
  
  
  
.799
  
  
  
  
ClassII 22 39.5 15.2 
Class III 12 42.0 18.6 
Class IV 9 39.4 20.2 
Total 59 41.3 15.5 
Serum Total       
Protein 
  
  
  
Class I 17 6.4 .2 20.476
  
  
  
  
.000
  
  
  
  
ClassII 22 6.3 .3 
Class III 12 5.9 .2 
Class IV 9 5.6 .4 
Total 60 6.2 .4 
Serum  Albumin 
  
  
  
  
Class I 17 3.5 .1 16.646
  
  
  
 
.000
  
  
  
 
ClassII 22 3.4 .2 
Class III 12 3.1 .2 
Class IV 9 2.9 .3 
Total 60 3.3 .3 
Prothrombin Time 
  
  
  
  
Class I 17 13.8 .9 15.706
 
 
 
 
.000
 
 
 
 
ClassII 22 14.3 2.9 
Class III 12 18.3 3.6 
Class IV 9 20.2 3.5 
Total 60 15.8 3.7 
  
 Serum ALP did not show a progressive rise in mean levels  with 
advancing heart failure.p value is.799 which is not significant. All other liver 
function tests showed a significant change in the mean values with worsening 
in heart failure class. p  values  were significant. 
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TABLE 15 
COMPARISON OF SERUM BILIRUBIN WITH ETIOLOGY OF 
CARDIAC FAILURE 
 
Etiology 
SERUM BILIRUBIN Total 
Abnormal Normal 
Frequency Percent Frequency Percent Frequency Percent
CAHD 14 60.9 9 39.1 23 100.0 
CP 8 57.1 6 42.9 14 100.0 
RHD 7 70.0 3 30.0 10 100.0 
CM 4 66.7 2 33.3 6 100.0 
HHD 1 14.3 6 85.7 7 100.0 
Total 34 56.7 26 43.3 60 100.0 
χ2 =6.255 df =4  p=0.181 
p value insignificant 
 Serum bilirubin  did not show much correlation with the etiology of 
cardiac failure. 
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TABLE 16  
COMPARISON OF SERUM BILIRUBIN WITH DURATION OF 
CARDIAC FAILURE 
 
Duration 
of illness 
SERUM BILIRUBIN Total 
Abnormal Normal 
Frequency Percent Frequency Percent Frequency Percent
<1 0 .0 1 100.0 1 100.0
1-5 18 51.4 17 48.6 35 100.0
>5 16 66.7 8 33.3 24 100.0
Total 34 56.7 26 43.3 60 100.0
χ2 =2.676 df =2  p=0.262  
p value is not significant 
No correlation was made out between serum bilirubin and duration of cardiac 
failure. 
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TABLE 17 
SHOWING COMPARISON OF MEAN BILIRUBIN WITH 
OUTCOME OF CARDIAC FAILURE 
Outcome Frequency 
Mean 
Bilirubin
S D T P value 
Dead 4 2.95 .68 3.603 
 
.001 
 Alive 56 1.65 .70 
 
 p value is 0.001 which is significant.Elevated serum bilirubin can be 
considered as a bad prognostic indicator of cardiac failure. 
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TABLE 18 
SHOWING COMPARISON BETWEEN VALUES ON FIRST DAY OF 
STUDY AND SEVENTH DAY OF STUDY 
 
LIVER  
FUNCTION 
TESTS 
DAY 1 DAY 7 McNemar 
test  P 
value 
 
Frequency Percent Frequency Percent 
Serum Bilirubin 34 56.7 14 25.0  <0.001 
Serum AST 32 53.3 16 28.6  0.002 
Serum ALT 37 61.7 19 33.9  <0.001 
Serum  ALP 8 13.3 7 12.5  1.000 
Serum TP 12 20.0 8 14.3  1.000 
Serum Albumin 23 38.3 27 48.2  0.424 
PROTHROMBIN 
TIME 
21 35.0 20 35.7 0.508 
 
p values are significant for Serum Bilirubin,Serum AST and Serum ALT 
which  showed considerable improvement in values  with control of failure 
symptoms and on  followup  at the end of 1 week. Serum total protein ,serum 
albumin and prothrombin time did not show significant change at the end of 1 
week. 
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DISCUSSION 
 Large number of studies has been conducted in evaluating hepatic 
function in congestive heart failure .Umpteen number of studies are still 
going on in this arena of liver function.   
 In this study ,liver biochemical abnormalities and clinical features in 
cardiac failure because of differing etiologies in 60 patients were recorded 
,analysed and compared within and correlated with  numerous research 
papers.The principal intention of this study is  to  relate indian picture with 
international  scenario.  
AGE AND SEX DISTRIBUTION OF THE CASES 
 Out of 60 patients studied  19 of them belonged to 46- 55 age group 
and 21 of them belonged to above 55 age group .This shows that cardiac 
disease  and progression into failure is more common in the elderly age 
group. Out of  60 subjects selected randomly  41 were males and 19 were 
females which shows the rise in cardiac disease and failure in the male 
population when compared to the opposite gender which is in correlation 
with the international scenario. Demographic and Clinical Characteristics of 
Patients Admitted  with Heart Failure  in the Euroheart Survey and ADHERE  
Programmes in the US  has shown increased incidence of heart failure in the 
elderly age group and the male population 1,5. The median age at first 
presentation in most recent studies has been in  the mid-70s, with a higher 
incidence in men than in women of all ages. Davies et al in his study    
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suggest that the occurrence of heart failure is nearly two  percent of the adult 
population, with a sharp increase with age. 
ETIOLOGY  AND DURATION OF CARDIAC FAILURE 
  In this study out of the 60 patients studied 23 patients ( 38.3%) 
suffered from coronary artery disease, 14 patients  from corpulmonale,10 
from rheumatic heart disease,6 from cardiomyopathy,7 from hypertensive 
heart disease.In this study most  common cause  for heart failure was found to 
be coronary artery disease which is in correlation with the international scene. 
The incidence of rheumatic heart disease as the reason for heart failure has 
declined which is considered as a changing trend in the etiology of heart 
failure.  Cowie et al and Fox et al  has shown in there studies the solitary 
most common cause of heart failure  in the developed world is coronary heart 
disease 1,5,44.  Kannel et al , McMurray et al and levy et al  in there studies 
suggest  valvular heart disease and hypertension have come down as the 
principal reason  for  heart failure5.  
 Out of 60 subjects studied the duration of cardiac failure was greater 
than 5 years in 24 cases (40%),was in the range of 1- 5 years in 38 cases 
(58.3) and less than 1year in 1 case(1.7%). 
NYHA CLASS   
 Out of the 60 patients studied 17 belong to class 1,22 belong to class 
2,12 belong to class 3,9 belong to class 4. Most of  the  patients  come  under  
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lower  clases than higher classes which suggests improved quality of life with 
cardiac failure medications as reported by Luis et al. 
JAUNDICE   
 Out of the 60 patients studied 20 subjects which is nearly 33% had 
jaundice. Other causes for jaundice like liver damaging drugs and alcohol 
related injury were excluded by taking proper history from the subjects. 
Serological tests were carried out to rule out viral causes for liver damage. 
Biegus et al has described jaundice clinically 33% of the cases. Similarly  
Kugel and Lichtman in 1933, Felder et al  in 1950,  chavez et al in 1943, 
Sherlock et al in 1951, Evans et al in 1952, Levine and Klatskin in 1964 has 
suggested in there papers that the serum bilirubin  was frequently above the 
upper limit of  normal range. 
HEPATOMEGALY 
 In  this  study  hepatomegaly  was found to be present in twenty five 
out of sixty subjects which is nearly 41.7%. The enlargement in liver ranged 
from 1cm to 8cm in these subjects. Dunn et al and white et al has 
demonstrated liver enlargement in more than 90% cases in there studies24. 
Richman et al and Sinha et  al  found liver enlargement which was above 5cm 
in nearly fifty percent cases11. 
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ASCITES 
  Out of 60 subjects only seven persons showed clinically detectable 
ascites which is  11.7%. Norman et al demonstrated ascites and oedema in 
15% of cases of cardiac failure studied12. 
ULTRASOUND ABDOMEN 
 USG Abdomen was carried out in all the 60 subjects.  23 (38.3%) of 
them showed changes of congestive hepatomegaly in the abdominal scan.  
HYPERBILIRUBINAEMIA 
 Elevated serum bilirubin values were detected in 34 out of 60 patients 
which is 56.7%.In this study most of them had bilirubin values less than 
3mg/dl. Serum bilirubin values were less than 3mg/dl in 55 cases and more 
than 3mg/dl in 5 cases. Those with values more than 3 showed features of 
severe congestive cardiac failure. It was seen that with control of cardiac 
failure the serum bilirubin levels returned to basal values in more than 50% 
of the cases In this study no specific correlation  (p value not significant) was 
found between etiology and mean serum bilirubin values though subjects 
with  rheumatic heart diseae showed  a slight increase in incidence of 
jaundice  followed by coronary heart disease . Hypertensive  heart  disease 
patients showed  least rise in serum bilirubin values. Similarly no significant 
correlation was found between duration of cardiac failure and mean serum 
bilirubin  values. 
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Felder et al has shown elevate bilirubin  levels in 52% of the cases in his 
study 10. Similarly Wahi et al and Naresh bhu have reported 
hyperbilirubinaemia in 45% and 58% of subjects respectively. Kubo et al 
have reported that bilirubin values rarely increase more than 5mg% and are 
usually less than 3 mg%26. Sherlock et al have also reported similar findings 
with  indirect  fraction more than direct fraction in his study .Richman et al 
has reported that control of cardiac failure  led to return of serum bilirubin 
values  to basal levels in nearly one week which correlates with the findings 
in this study16. 
 In this study it was noted that as the NYHA Class of heart failure 
advanced the mean serum bilirubin level also progressively increased which 
suggests higher classes of heart failure were  associated  with higher degree 
of liver dysfunction This was supported by  Luiz  et al in their study43. 
SERUM  AMINOTRANSFERASES. 
 In the present study 32 subjects (53.3%) showed increased AST levels 
and 37 subjects  (61.7%)  showed raised ALT levels. The rise in AST levels 
ranged from 40-910 IU which correlates with the findings of Richman et al 
who observed  striking rise in transaminase in cardiac failure secondary to cor 
pulmonale or tricuspid regurgitation or hypotension and shock . Dunn et al 
and Richman et al have observed  that  rise in serum ALT is noted in 5-50% 
of patients  and it is seen more in acute heart failure than chronic heart 
failure. In  this study it has been observed that  mean  AST levels increase 
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progressively as the NYHA class of cardiac failure progresses. Serum AST 
levels showed significant elevation in the class IV heart failure which 
correlates with the observations of the Luiz  et al  and walter et al. With 
control of cardiac failure more   than   50% values came to the baseline 
values. 
SERUM   ALKALINE  PHOSPHATASE 
 In this study out of the 60 subjects studied eight patients showed 
abnormal serum ALP (13.3%). Felder et al observed elevated serum ALP in 
ten – twenty percent of subjects studied10. Sherlock and Richman has 
recorded similar observations in their studies12. Rise in serum ALP does not 
relate with the elevation in serum transaminases and bilirubin. ALP values 
return to basal level with control of failure symptoms. Serum ALP values 
showed no correlation with the NYHA Classes of cardiac failure. It was 
observed that mean ALP levels showed no progressive  change with 
worsening of heart failure. 
 In the present study serum AST and ALT showed marked elevation 
than serum ALP thus suggesting a predominant hepatocellular pattern of 
hepatic damage.  
SERUM PROTEINS  
 In this study 23 subjects showed hypoalbuminaemia out of 60 subjects 
ie 38.3% and 4 cases showed abnormal globulin.AG Reversal was noted in 4 
cases. It was noted that with advancement in class of cardiac failure mean 
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serum albumin levels showed a progressive fall with class IV patients 
showing the lowest mean serum albumin value with a significant p value. 
Richman et al in his study has reported decreased albumin in thirty – fifty 
percent of cases.Mild decrease in albumin levels were observed with values 
ranging from 2.5g/dl to 2.9g/dl.it was observed by Dunn et al that cases with 
marked fluid retention showed albumin values less than 1.5g/dl24. Serum 
albumin values  usually return to normal in a period of few months following 
control of cardiac failure. 
 Elevated globulin values were noted in 35-50% of subjects with right 
heart failure by Richman et al. A mild rise was noted in most of the cases 
ranging from 3.5 -4.1g/dl. A rise in globulins and fall in albumin causes 
reversal of Albumin globulin ratio.It was found that unlike other parameters 
globulin values did not return to normal value following control of cardiac 
failure. 
PROTHROMBIN TIME 
 In this study 21 out of 60 patients showed prolongation in prothrombin 
time(35%).most of the values were 1.5 – 2 times the normal value.Following 
treatment prothrombin time  repeated at the end of 1 week did not show any 
improvement. Mean prothrombin time also showed progressive increase with 
worsening of cardiac failure such that class IV cases showed highest mean 
prothrombin time. White et al as described prolonged prothrombin time in 
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nearly 85% of the subjects.it was reprted that prothrombin time come to 
baseline values usually two – three weeks after control of cardiac failure. 
OUTCOME 
 Out of 60 cases studied 4 cases succumbed to the cardiac illness during 
the course of illness .The mean bilirubin value of these cases were 2.95 which 
was more when compared to other subjects which was 1.65 with a p value of 
.001 which is significant suggesting that elevated bilirubin levels can be taken 
as a bad prognostic marker in congestive cardiac failure. 
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CONCLUSIONS 
1. The most common cause of  congestive cardiac failure  in patients 
presenting to Tirunelveli Govt Medical College Hospital was found to 
be  Coronary artery disease. 
2. Elderly Male population were found to have an increased incidence of 
cardiac failure when compared to the opposite gender. 
3. Liver function abnormalities were found in 56.7% of  the total 
congestive cardiac failure patients included in this  study. 
4. Liver function abnormalities did not show any correlation with the 
aetiology and duration of cardiac failure though subjects with 
rheumatic heart disease showed a mild increase in incidence of 
abnormal liver function. Least incidence of liver function abnormalities 
were found in Hypertensive heart disease patients. 
5. Serum AST was found to be abnormal in 53.3% of the subjects and 
serum ALT was abnormal in 61.7% of the cases whereas serum ALP 
was found to be abnormal   only in 13.3% of cases.This suggest a 
predominant hepatocellular pattern of liver injury  than cholestatic 
pattern.  
6. Serum albumin was found to be decreased in 38.3 % of the subjects  
and serum globulin was abnormal in 6.7% of cases and A G reversal 
was noted in 4 cases.Prolongation of prothrombin time was observed in 
35% of cases . 
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7. Mean  serum Bilirubin , AST and ALT values  when compared with 
NYHA Class of heart failure showed a progressive increase  with the 
advancement of heart failure . Mean serum ALP values did not show 
any correlation with NYHA Class of heart failure. Mean serum 
albumin values showed a progressive  fall  with advancement of 
cardiac failure.Prothrombin time also showed progressive prolongation 
with worsening of failure class. Thus  Class IV heart failure patients 
showed  a higher degree of predominant hepatocellular pattern of liver 
damage. 
8. With control of failure and on follow up after one week serum bilirubin 
and serum enzymes showed considerable improvement whereas serum 
albumin and prothrombin time did not show any significant change. 
9. Out of the 60 subjects studied 4 cases succumbed to the cardiac illness 
and rest of them showed improvement at the end of 1 week. On 
comparison of  mean bilirubin value  with the outcome  it was 
observed that  higher values were associated with a poor prognosis. 
Thus serum bilirubin was found to have prognostic significance in 
cardiac failure. 
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PROFORMA 
 
Name  
Age  
Sex  
I P NO: 
 
PRESENTING COMPLAINTS                                                      
DURATION 
Chest pain                  : 
Breathlessness                   : 
Palpitations                                 : 
Syncope                               : 
Cough                                         : 
Haemoptysis                               :  
Swelling of legs                          :  
Oliguria                                      :  
Fever                                           :  
Other symptoms                         :  
PAST HISTORY  
Similar illness in the past  
Diabetes mellitus  
Hypertension  
Coronary artery heart disease  
Bronchial asthma  
Jaundice  
Rheumatic fever  
Pulmonary tuberculosis  
Transient ischaemic attacks  
 
 
 
Abortion / Exposure to sexually transmitted diseases  
PERSONAL HISTORY  
Smoking  
Alcoholism  
FAMILY HISTORY  
Hypertension  
Diabetes mellitus  
Coronary artery heart disease  
CLINICAL EXAMINATION  
Consciousness  
Orientation  
Temperature  
Anaemia  
Jaundice  
Cyanosis  
Clubbing  
Pedal edema  
Lymph node enlargement  
Jugular venous pressure  
Signs of infective endocarditis  
Signs of liver failure  
VITAL PARAMETERS 
Pulse  
Blood pressure  
Respiratory rate 
CARDIOVASCULAR SYSTEM  
Heart sounds and murmurs 
Parasternal heave  
Abnormal pulsations                                                                                                               
 
 
 
RESPIRATORY SYSTEM  
Respiratory rate  
Breath sounds  
Added sounds  
ABDOMEN  
Appearance  
Ascites  
Hepatomegaly  
Spleenomegaly  
CENTRAL NERVOUS SYSTEM  
Higher functions  
Cranial nerves  
Spinomotor system  
Sensory system  
Cerebellar system  
Spine and cranium 
DIAGNOSIS  
 Onset of illness Acute  
 Chronic  
 Acute on chronic  
 Duration of illness < 1 Year  
 1-5 Years  
 > 5 Years  
INVESTIGATIONS  
Blood hemogram  
Urine routine  
Blood sugar  
Blood urea and serum creatinine  
Serum electrolytes  
 
 
 
HBs Ag  
Anti HCV Abs  
Electrocardiography  
Chest x ray  
  13. LIVER FUNCTION TESTS 
 S.Bilirubin- Total  
 Direct  
 Indirect  
 SGOT  
 SGPT  
 Alkaline Phosphatase  
 Total Proteins  
 Albumin  
 Globulin  
 AG ratio  
 Prothrombin time  
14. USG abdomen 
 
 
 
 
 
 
 
 
MASTER CHART 
SL 
NO NAME AGE SEX 
ETIOL
OGY 
DURATION 
J H A
Class 
of 
CCF 
S.BIL AST ALT SAP S.PROTEINS PRO.T 
USG 
ABD 
1 `5 ~5 D1 D7 D1 D7 D1 D7 D1 D7 
D 1 D 7 D1 D7 
T A G T A G C T C T 
1 SELVARAJ 45 M CAHD  *  - + - 4 3.6 1.5 910 180 636 98 41 40 6 3.2 2.8 6.2 3.2 3 12 24 12 22 + 
2 KASIPANDI 53 M CAHD  *  - - - 2 1.8 1.2 41 32 36 30 19 28 6.5 3.7 2.8 6 3.2 2.8 14 12 14 14 - 
3 MUTHUSAMI 58 M CP   * - - - 3 1.6 1.2 42 40 35 33 29 29 6 3.2 2.8 6 3 3 14 14 14 16 - 
4 LAKSMI 39 F RHD   * + + + 4 2.6 1.4 59 40 47 38 19 17 5.2 2.7 2.5 5.4 2.9 2.5 14 22 14 24 + 
5 KUMAR 48 M CAHD  *  - + - 2 1.4 1.2 44 38 38 32 14 14 6.5 3.5 3 6.2 3.2 3 14 12 12 12 + 
6 CHINNASAMI 40 M CM  *  + + + 4 2.8 1.8 98 142 68 128 18 14 6.4 3.4 3 6.8 3.6 3.2 14 12 14 14 + 
7 VALLI 46 F HHD   * - - - 1 1.2 1.0 38 32 36 31 21 16 6.2 3.4 2.8 6.4 3.4 3 12 14 12 14 - 
8 PANDI 51 M CAHD *   - - - 2 1.0 0.8 44 38 38 36 18 16 6.2 3.2 3 6 3.2 2.8 14 14 14 14 - 
9 MARIAMMAL 48 F CAHD  *  - - - 2 1.8 1.4 48 42 44 38 14 12 6.4 3.4 3 6 3 3 14 16 14 14 - 
10 GANESAN 58 M CP   * - + - 3 2.4 1.4 40 38 38 36 12 10 5.8 3. 2.8 6.0 3.2 2.8 14 16 14 16 + 
11 RAMU 44 M RHD   * - + - 3 2.8 1.4 182 48 148 34 39 35 5.6 3.2 2.4 6.0 3.4 2.6 14 14 14 14 + 
12 KANNAN 51 M CAHD  *  - - - 2 1.2 .8 29 26 26 24 38 34 6.5 3.5 3 6.5 3.5 3 14 14 14 12 - 
13 GOMATHI 56 F CM  *   +  3 2.8 1.4 148 48 126 36 30 30 5.6 2.6 3 6.4 3.0 3.4 14 22 14 22 - 
14 SAMUEL 59 M CP  *   +  4 3.2 2 88 36 78 32 30 28 5.2 3.2 2 5.4 3.2 2.2 14 22 14 22 + 
15 SAROJA 30 F HHD  *     1 1.4 .8 41 41 32 29 33 31 6.5 3.5 3 6.6 3.6 3 14 14 14 14 - 
16 SHEIK AHAMMED 52 M CAHD  *   +  4 3.4 1.4 93 42 83 32 38 35 5.4 2.4 3 6 2.8 3.2 14 18 14 16 + 
17 DEVI 28 F RHD   *  +  3 2.8 1.2 84 44 76 32 30 36 5.8 3. 2.8 6 3.2 2.8 14 22 14 20 + 
18 POOMANI 49 F CAHD  *   _  1 1.4 1.2 38 33 34 31 44 43 6.5 3.5 3 6.6 3.6 3 14 14 14 12 - 
19 ARJUNAN 62 M CP   *  -  2 1.8 1.4 32 28 30 26 34 32 6.5 3.5 3 6.5 3.5 3 14 12 14 14 - 
20 DURAI 34 M CM  *  + + + 4 3.2 3.2 156 243 97 168 32 38 5.2 2.8 2.4 5.4 3 2.4 14 22 14 24 + 
21 MARIYAM 38 F RHD   * - - - 1 .8 .8 30 32 37 31 34 32 6 3.3 2.7 6 3.5 3 14 13 14 14 - 
22 ESTHER 62 F CAHD  *  + + - 4 2 2.2 87 135 75 125 33 39 5.4 2.8 2.6 5.4 2.6 2.8 14 22 14 24 + 
23 SELVAM  72 M CP   *  + - 2 1.9 .8 42 38 32 32 38 34 6 3.5 2.5 6.2 3.2 3 14 22 14 20 + 
24 RAMIAH 48 M CAHD  *   + - 2 1.8 1.2 54 38 44 36 38 36 6 3 3 6.2 3.2 3 12 18 12 20 + 
25 SUBBIAH 54 M CAHD  *   +  2 2.2 1.2 42 40 34 30 31 32 6.4 3.4 3 6.5 3.4 3.1 14 14 12 14 + 
26 ISMAIL 59 M CP  *   -  1 .9 .8 38 34 36 30 39 38 6.5 3.5 3 6.4 3.4 3 14 16 14 14 - 
27 IBRAHIM 68 M CAHD   *  +  2 2 2.4 38 52 44 58 31 38 6 3.4 2.6 5.6 3 2.6 14 22 14 24 - 
28 AMBIKA 54 F CAHD  *     1 .8 .8 38 34 34 32 33 34 6.5 3.5 3 6.5 3.5 3 14 12 14 14 - 
29 SUGUNAN 42 M CM  *  - - - 1 1.0 .8 42 37 38 32  47 6.2 3.2 3 6.5 3.5 3 14 12 14 14 - 
30 MANI  75 M CAHD   * - - - 2 1 .7 41 39 38 36 48 44 6.2 3.2 3 6.4 3.4 3 14 14 14 16 - 
31 KALIAMMAL 37 F RHD   * - - - 2 1.2 .8 44 42 38 36 34 31 6.4 3.4 3 6.2 3.2 3 14 14 14 12 - 
32 PARAMESHWARI 56 F CAHD  *  + + - 3 2.4 1.8 93 43 88 38 43 38 6 3.2 2.8 6 3.2 2.8 14 22 14 20 + 
33 GANESHAN 60 M CP  *   + + 2 2.2 1.2 38 32 44 42 38 36 5.4 2.6 2.8 5.4 2.8 2.6 14 14 14 14 + 
34 CHELLADURAI 58 M HHD   * - - - 2 1.1 1 36 32 38 34 44 42 6.5 3.5 3 6.5 3.5 3 14 12 14 14 - 
35 NAINAR 55 M CAHD  *  - - - 1 1 1 38 34 36 32 44 41 6.4 3.4 3 6.4 3.4 3 14 14 14 16 - 
36 KRISHNAN 65 M CP  *  - - - 2 1.2 1 44 36 38 36 48 46 6.4 3.4 3 6.2 3.2 3 14 12 14 14 - 
37 REHMAN 29 M RHD  *  - - - 2 1.4 1.2 34 32 28 26 48 34 6.5 3.5 3 6.5 3.6 2.9 14 12 14 14 - 
38 KUMARESAN 60 M CP   * - - - 2 1.2 1 35 32 26 24 48 43 6 3.2 2.8 6 3.2 2.8 14 12 14 14 - 
39 REMANI 55 F CAHD  *  - - - 1 1 1 34 34 28 26 46 44 6.5 3.5 3 6.5 3.5 3 14 14 14 16 - 
40 BEER MOIDEEN 52 M CP  *  - - - 1 1.2 1 36 32 28 24 48 46 6.8 3.8 3 7 4 3 14 14 14 14 - 
41 RASATHI 56 F CAHD   * - + - 3 2.4 1.4 84 73 98 96 58 55 5.8 2.8 3 5.8 3 2.8 14 14 14 16 + 
42 SANKARAN 62 M CM  *   +  3 2.2 1.2 88 82 86 81 38 34 6. 3.2 2.8 6 3.4 2.6 14 22 14 24 + 
43 VELLACHAMY 70 M CP   *    2 1.4 1.2 38 34 32 30 48 46 6.4 3.4 3 6.2 3.2 3 14 14 14 14 - 
44 RAJAM 35 F RHD   *    1 1.2 1 38 33 28 25 49 45 6.5 3.5 3 6.5 3.5 3 14 14 14 14 - 
45 PONNAIAH 58 M HHD  *     1 1.2 1 39 33 28 26 48 44 6.4 3.4 3 6.4 3.2 3.2 14 14 14 16 - 
46 ANNAMALAI 50 M CAHD  *  - + - 1 1.2 1 36 32 28 26 44 42 6 3.4 2.6 6.2 3.6 2.6 14 14 14 16 + 
47 MAHESH 27 M RHD   * - + _ 3 1.8 1,2 88 68 94 92 45 43 6 3.4 2.6 6.2 3.6 2.6 14 20 14 16 + 
48 SUNDARAM 58 M CP  *  - - - 2 1.2 1 38 35 28 24 48 44 6.3 3.3 3 6.2 3.2 3 14 12 14 14 - 
49 SANTHI 56 F HHD  *     1 1 1 34 32 28 26 56 53 6.4 3.6 2.8 6.4 3.6 2.8 14 14 14 14 - 
50 SREENI 63 M CP   *  +  3 1.6 1.2 68 60 70 66 43 42 6.2 3.2 3 6 3.2 2.8 14 14 14 14 - 
51 KARPAGAM 56 F CAHD  *  - - - 1 0.8 0.8 29 24 28 26 47 54 6.5 3.5 3 6.6 3.6 3 14 14 14 14 - 
52 VELCHAMI 52 M CAHD   * + + + 4 3 2.8 120 97 117 88 78 79 5.8 2.8 3 5.8 2.8 3 14 20 14 16 + 
53 THAJUDEEN 62 M CP  *  - - - 2 0.9 0.9 38 32 32 28 56 54 6.4 3.4 3 6.2 3.4 2.8 14 14 14 12 - 
54 MARISELVI 36 F RHD   * - - + 3 2.8 1.6 88 43 76 38 88 89 6 3 3 6.2 3.2 3 14 21 14 14 + 
55 ARSUNAN 51 M HHD  *  - - - 1 1.1 1 39 32 34 28 55 54 6.5 3.5 3 6.5 3.5 3 14 14 12 14 - 
56 NALLASAMY 49 M CAHD  *  - - - 1 1 1 39 32 37 32 67 56 6.6 3.6 3 6.6 3.6 3 14 14 12 14 - 
57 NALLA KANNU 36 M CM  *  - - - 2 1.2 1.2 39 37 32 28 78 72 6.5 3.5 3 6.5 3.5 3 14 14 14 14 - 
58 DEVANAYAGAM 62 M CAHD   * + + + 4 2.6 1.2 88 74 77 64 66 55 6 3 3 6 3 3 14 20 14 20 + 
59 IBRAHIM 28 M RHD   * + - _ 3 2.1 1.4 45 33 37 31 49 48 6.2 3.2 3 6.3 3.3 3 14 18 14 16 - 
60 RAJAM 52 F HHD   * - - - 2 1 1 38 36 27 21 55 51 6.8 3.8 3 7 4 3 14 14 14 14 - 
 
